The Switzerland-based firm, which is a clinical-stage oncology-focussed biopharmaceutical company, has received approval for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to study its oral Dihydroorotate dehydrogenase (DHOHD) inhibitor for SARS-CoV-2 infection, Rhizen Pharmaceuticals S A said in a statement.Rhizen Pharma gets USFDA approval for phase one clinical trials for COVID-19 drug
The Switzerland-based firm, which is a clinical-stage oncology-focussed biopharmaceutical company, has received approval for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to study its oral Dihydroorotate dehydrogenase (DHOHD) inhibitor for SARS-CoV-2 infection, Rhizen Pharmaceuticals S A said in a statement.
Subscribe to:
Post Comments (Atom)
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
No comments:
Post a Comment